Condition
Internuclear Ophthalmoplegia
Total Trials
5
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 3 (1)
Trial Status
Not Yet Recruiting2
Terminated1
Completed1
Suspended1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05338450Phase 3Terminated
Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis
NCT07560995Not Yet Recruiting
Internuclear Ophthalmoplegia and Multiple Sclerosis: a Multicenter Retrospective Study
NCT06417216Not ApplicableSuspendedPrimary
Head-Cancelled Virtual Reality for Ocular Cranial Nerve Palsies
NCT06629155Not Yet Recruiting
Studying Eye Movement Deficits and Cognitive Impairment in Patients with Multiple Sclerosis Using Infrared Eye Tracking and Cognitive Tests
NCT02391961Phase 2Completed
Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis
Showing all 5 trials